Clinical implications of antibiotic pharmacokinetic-pharmacodynamic parameters

被引:3
|
作者
Cohen, R. [1 ,2 ]
机构
[1] Hop Intercommunal Creteil, Microbiol Serv, F-94010 Creteil, France
[2] Assoc Clin & Therapeut Infantile Val Marne ACTIV, F-94010 Creteil, France
来源
ARCHIVES DE PEDIATRIE | 2008年 / 15卷
关键词
D O I
10.1016/S0929-693X(08)74216-7
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The progress in the knowledge of antibiotic action mechanism have led to determine phamacodynamic/pharmacokinetic (PK/PD) parameters predictive of antibiotic efficacy in bacterial infections. These parameters could vary according to the antibiotic compound, the bacterial specie implicated, the localization of the infection, the severity of the disease. The serum PK/PD parameters are predictive of efficacy in several infections (respiratory, skin, bone) and become a major criterion for selecting antibiotics in clinical practice. Moreover, these PK/PD parameters are the cornerstone of pre-clinical development of antibiotics, the determination of dosage and for the establishment of breakpoints for classifying strains in the sensitive or resistant area, (C) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:S53 / S58
页数:6
相关论文
共 50 条
  • [31] Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development
    Dingemanse, Jasper
    Krause, Andreas
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 109 : S53 - S58
  • [32] Evaluation of a pharmacokinetic-pharmacodynamic approach using software to optimize the carbapenem antibiotic regimen
    Ishihara, Noriyuki
    Nishimura, Nobuhiro
    Tamaki, Hiroki
    Karino, Funni
    Miura, Kiyotaka
    Isobe, Takeshi
    Ikawa, Kazuro
    Morikawa, Norifumi
    Naora, Kohji
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (06) : 422 - 429
  • [33] Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications
    Tsala, Marilena
    Vourli, Sophia
    Kotsakis, Stathis
    Daikos, George L.
    Tzouvelekis, Leonidas
    Zerva, Loukia
    Miriagou, Vivi
    Meletiadis, Joseph
    JOURNAL OF MEDICAL MICROBIOLOGY, 2016, 65 : 211 - 218
  • [34] CONCEPTS AND USEFULNESS OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING
    HOLFORD, NHG
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1990, 4 : S93 - S101
  • [35] Pharmacokinetic-pharmacodynamic model for educational simulations
    van Meurs, WL
    Nikkelen, E
    Good, ML
    IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 1998, 45 (05) : 582 - 590
  • [36] APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING TO ANALGESIA
    INTURRISI, CE
    COLBURN, WA
    ADVANCES IN PAIN RESEARCH AND THERAPY, 1986, 8 : 441 - 452
  • [37] PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS OF MORPHINE IN NEONATES
    CHAY, PCW
    DUFFY, BJ
    WALKER, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) : 334 - 342
  • [38] Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys
    Haritova, A. M.
    Rusenova, N. V.
    Parvanov, P. R.
    Lashev, L. D.
    Fink-Gremmels, J.
    VETERINARY RESEARCH COMMUNICATIONS, 2006, 30 (07) : 775 - 789
  • [39] Gliclazide:: Pharmacokinetic-pharmacodynamic relationships in rats
    Stetinova, V.
    Kvetina, J.
    Pastera, J.
    Polaskova, A.
    Prazakova, M.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (05) : 241 - 248
  • [40] Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models
    Siripuram, Vijay K.
    Wright, Daniel F. B.
    Barclay, Murray L.
    Duffull, Stephen B.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (05) : 415 - 423